Key Publications

Selected TF Publications

(2023) Weining W, Tao M, Qianqian Z, Yi S, Guoxiang F, Jing S, Yue Z, Zhaohui W, Mingqiao W, Rong P, Linjie M, Caiwei C, Lijun W, Biao Z, Hui Z, Junyi P, Jianjian Z, Yi Peter H, Guoqiang H, Yu Q, Shu-Hui L, Wenhao H, Xun M. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discovery, 2023 Apr 3;13(4):950-973. doi: 10.1158/2159-8290.CD-22-1368. PMID: 36693125

(2022) de Bono JS, Harris JR, Burm SM, Vanderstichele A, Houtkamp MA, Aarass S, Riisnaes R, Figueiredo I, Nava Rodrigues D, Christova R, Olbrecht S, Niessen HWM, Ruuls SR, Schuurhuis DH, Lammerts van Bueren JJ, Breij ECW, Vergote I. Systematic study of tissue factor expression in solid tumors. Cancer Rep (Hoboken), 2023 Feb;6(2):e1699. doi: 10.1002/cnr2.1699. PMID: 36806722

Selected uPARAP Publications

(2024) Gregersen I, Loekke C, Lange JB, Barkholt P, Come C, Broberg T, Petersen MM, Lynch CM, Mumberg D, Behrendt N, Engelholm L. Urokinase plasminogen activator receptor-associated protein (uPARAP) is overexpressed in human glioblastomas and is a therapeutic target for antibody-drug conjugates (ADC). Cancer Research 84(6_Supplement):6355-6355. DOI:10.1158/1538-7445.AM2024-6355.

(2023) Barkholt P, Wozniak A, Wang C-C; Lee C-J,De Kock L, Engelholm LH, Lynch C, Mumberg D, Schöffski P. The urokinase plasminogen activator receptor-associated protein (uPARAP) is an attractive target for the development of antibody-drug conjugates (ADCs) for treatment of mesenchymal malignancies. Cancer Res (2023) 83 (7_Supplement): 1547. https://doi.org/10.1158/1538-7445.AM2023-1547.

(2022) Gucciardo, F, Pirson S, Baudin L, Lebeau A, Noël A. uPARAP/Endo180: a multifaceted protein of mesenchymal cells. Cell Mol Life Sci 2022 Apr 22;79(5):255. doi: 10.1007/s00018-022-04249-7. PMID: 35460056 PMCID: PMC9033714.

(2022) Evans RJ, Perkins DW, Selfe J, Kelsey A, Birch GB, Shipley JM, Schipper K, Isacke CM. Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma. Mol Cancer Ther. 2023 Feb 1;22(2):240-253. doi: 10.1158/1535-7163.MCT-22-0312. PMID: 36399638. PMCID: PMC9890142.

(2017) Nielsen CF, van Putten SM, Lund IK, Melander MC, Nørregaard KS, Jürgensen HJ, Reckzeh K, Christensen KR, Ingvarsen SZ, Gårdsvoll H, Jensen KE, Hamerlik P, Engelholm LH, Behrendt N. The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers. Oncotarget. 2017 Jul 4;8(27):44605-44624. doi: 10.18632/oncotarget.17883. PMID: 28574834; PMCID: PMC5546505.

(2002) Schnack Nielsen B, Rank F, Engelholm LH, Holm A, Danø K, Behrendt N. Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. Int J Cancer. 2002 Apr 10;98(5):656-64. doi: 10.1002/ijc.10227. PMID: 11920633.

(2000) Behrendt N, Jensen ON, Engelholm LH, Mørtz E, Mann M, Danø K. A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem. 2000 Jan 21;275(3):1993-2002. doi: 10.1074/jbc.275.3.1993. PMID: 10636902.